Sun Pharmaceutical Industries Ltd. closed 13.70% below its 52-week high of 1,960.20 rupees, which the company achieved on September 30th.

Sun Pharmaceutical Industries Ltd. closed 13.62% below its 52-week high of 1,960.20 rupees, which the company reached on September 30th.

Welcome to the Sun Pharma Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ahead of the market with our in-depth coverage of Sun Pharma, including ...

Richard Ascroft has been appointed CEO of Sun Pharma North America. - PROVIDED BY SUN PHARMA ...

Incyte CEO passes the baton. String of FDA leadership shake-ups continues. Sun Pharma sees bright future with new North America CEO.

PRINCETON, N.J., June 25, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries ...

As North America CEO, Richard will advance Sun Pharma's diverse portfolio of innovative medicines, generics and over-the-counter products in both the U.S. and Canada. With a background spanning ...

Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for over 18% of company sales.